retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 What Is (RETA)? The Explained Eli Lilly's retatrutide shows promising

One prospective RCT involving 665 patients with T2DM randomized to 2 doses of semaglutide versus physician's choice of additional antidiabetic agent (OAD) found no increase in cancer compared to OAD, though followup was only 56 weeks

[DOI] [PMC free article] [PubMed] [Google Scholar] 24.Saran A, et al

Because the two drug classes use different metabolic pathways, direct drug-drug interactions are uncommon

Obese patients are more likely to see knee arthritis due to stress on the joints caused by their weight, which leads to cartilage breakdown and inflammation

Figure 16: Painting of Professor John C Brown (19382016) by his grandson, Matthew T Kieffer, credit: Kieffer

35 , 36 Despite the high risk of nonadherence, patients with prediabetes and in GLP1 RA treatment were not associated with an increased risk of addon glucoselowering treatment, which could be indicative of an effective weight reduction and control of the HbA1c simply weight reduction, or adverse effects